...
SMMTLARGE

Summit Therapeutics Inc.

HealthcareBiotechnology
$16.59
$0.01(+5.00%)
52W$13.83
$36.91
FinancialsValuationvs BNTX
Updated Mar 1, 12:00 AM
RSI50
RS Rating25/99
Beta1.40
Volatility93%
F-Score1/9
Mkt Cap$12.9B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

Summit Therapeutics Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 25), showing significant lag compared to the market leaders. Earnings contraction of 237% provides fundamental context to the price action. Investors should exercise caution due to high volatility (93% annualized), which requires wider risk management.

Relative Strength
25
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
1.40
vs S&P 500
ABOVE MKT
52W Position
12%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$16.51
50 SMA > 100 SMA$17.67
100 SMA > 150 SMA$19.64
150 SMA > 200 SMA$20.52

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$15.22+8.98%ABOVE
50 SMA$16.51+0.47%ABOVE
100 SMA$17.67-6.12%BELOW
150 SMA$19.64-15.52%BELOW
200 SMA$20.52-19.13%BELOW

Price Performance

1D+5.0%
1W+3.1%
1M+6.1%
3M-7.3%
6M-32.1%
YTD-5.3%
1Y-19.8%
3Y+109.7%
52-Week Trading Range12% from low
$16.59
52W Low$13.83
52W High$36.91

Technical Indicators

RSI (14)NEUTRAL
50.1
305070
VCP ScoreCOOL
4/10
Base depth: 38.4%

Risk Profile

Beta
1.40
52W Vol
93%
ATR
$0.76
Max DD (1Y)
-62%

Volume Analysis

Today
16
50D Avg
2.33M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25-38%
$-0.09
Q2'25-791%
$-0.76
Q3'25-301%
$-0.31
Q4'25-237%
$-0.28
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:—

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-366.58%

Stock Price CAGR

10 Years:+9.41%
5 Years:+20.17%
3 Years:+109.66%
1 Year:-19.82%

Return on Equity

10Y Avg:-193.4%
5Y Avg:-217.4%
3Y Avg:-301.0%
Last Year:-163.9%

Key Metrics

Market Cap$12.9B
Gross Margin—
Net Margin—
Piotroski F-Score1/9

More SMMT Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SMMT vs BNTXBNTXMRNAPCVXCDTX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 25 meansSMMT outperformed 25% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.40 means 40% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 1/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is SMMT in an uptrend right now?

SMMT has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is SMMT overbought or oversold?

SMMT's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.

Is SMMT outperforming the market?

SMMT has a Relative Strength (RS) Rating of 25 out of 99. SMMT is currently lagging the broader market.

Where is SMMT in its 52-week range?

SMMT is trading at $16.59, which is 45% of its 52-week high ($36.91) and 12% above its 52-week low ($13.83).

How volatile is SMMT?

SMMT has a Beta of 1.40 and 52-week volatility of 93%. It's more volatile than the S&P 500 - expect bigger swings.